肝癌介入治疗应用重组人5型腺病毒注射液的临床研究

Clinical study of recombinant human 5 type adenovirus injection in the interventional therapy of liver cancer

目的:研究重组人5型腺病毒注射液在肝癌介入治疗中的临床效果。方法:收治中晚期肝癌患者84例,随机分为对照组与研究组各42例。对照组在数字减影血管造影(DSA)引导下行肝动脉化疗剂与栓塞剂灌注,研究组在此基础上配合重组人5型腺病毒注射。对两组患者的疗效、AFP阳性率及不良反应进行分析。结果:研究组的临床总缓解率显著高于对照组(P<0.05);治疗后,两组患者的AFP阳性率均有所降低(P<0.05),研究组降低更明显(P<0.05)。结论:重组人5型腺病毒注射液在肝癌介入治疗中安全、可靠,临床总缓解率高。

Objective:To study the clinical effect of recombinant human 5 type adenovirus injection in the interventional therapy of liver cancer.Methods:84 patients with middle and late stage liver cancer were selected.They were randomly divided into the control group and the study group with 42 cases in each.The control group was given hepatic artery chemotherapy agent and embolization agent perfusion under the guidance of digital subtraction angiography(DSA).On this basis,the study group was given recombinant human 5 type adenovirus injection.The curative effects,AFP positive rates and adverse reactions of two groups were analyzed.Results: The clinical total remission rate of the study group was significantly higher than that of the control group(P<0.05).After treatment,the AFP positive rates of two groups were all decreased(P<0.05),and the reduction of the study group was more significant(P<0.05).Conclusion:Recombinant human 5 type adenovirus injection in the interventional therapy of liver cancer is safe and reliable,and the clinical total remission rate is high.